본문 바로가기
KERD
논문KCI 등재

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Ming-Lung Yu|Chung-Feng Huang
대한간학회 (The korean Association for the Study of the Liver)|2020.07|Clinical and Molecular Hepatology|제26권 제3호|pp. 251-260|DOI https://doi.org/10.3350/cmh.2020.0018

1

조회

0

다운로드

6

인용

0

참고문헌

키워드

TreatmentHepatitis C virusDirect-acting antivirals

초록

The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs. Nevertheless, there are still some unmet needs and emerging issues in the treatment of CHC in the DAA era. Certain hard-to-cure populations are prone to have inferior treatment responses, including patients with severe liver decompensation, active hepatocellular carcinoma (HCC), and hepatitis C virus (HCV) genotype 3 (HCV-3) infection and those who experience multiple DAA treatment failures. Hepatitis B virus (HBV) reactivation during and after DAA treatment has raised concern regarding the use of prophylactic antivirals against HBV throughout DAA treatment. However, the standard strategy for the use of prophylactic antivirals is not uniform across regional guidelines. In the post-sustained virological response (SVR) period, HCC still occurs in a substantial proportion of patients. Due to the relatively short follow-up period, the net benefit of the achievement of an SVR by DAAs in the reduction of extrahepatic manifestations has not yet been determined. Attention must also be paid to HCV reinfection, particularly in high-risk populations. The most critical and unmet need for HCV elimination is the large gap in the HCV care cascade at the population level. To accomplish the World Health Organization (WHO)’s goal for HCV elimination by 2030, the expansion of access to HCV care requires a continuous effort to overcome practical and political challenges.

Abstract

The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs. Nevertheless, there are still some unmet needs and emerging issues in the treatment of CHC in the DAA era. Certain hard-to-cure populations are prone to have inferior treatment responses, including patients with severe liver decompensation, active hepatocellular carcinoma (HCC), and hepatitis C virus (HCV) genotype 3 (HCV-3) infection and those who experience multiple DAA treatment failures. Hepatitis B virus (HBV) reactivation during and after DAA treatment has raised concern regarding the use of prophylactic antivirals against HBV throughout DAA treatment. However, the standard strategy for the use of prophylactic antivirals is not uniform across regional guidelines. In the post-sustained virological response (SVR) period, HCC still occurs in a substantial proportion of patients. Due to the relatively short follow-up period, the net benefit of the achievement of an SVR by DAAs in the reduction of extrahepatic manifestations has not yet been determined. Attention must also be paid to HCV reinfection, particularly in high-risk populations. The most critical and unmet need for HCV elimination is the large gap in the HCV care cascade at the population level. To accomplish the World Health Organization (WHO)’s goal for HCV elimination by 2030, the expansion of access to HCV care requires a continuous effort to overcome practical and political challenges.

참고문헌 (73)

  1. Huang JF, "Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?", Expert Rev Anti Infect Ther, 16, pp.907~912 (2018)
  2. Foster GR, "Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection", N Engl J Med, 373, pp.2608~2617 (2015)
  3. Hezode C, "Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir", velpatasvir in the phase III studies, 2018, pp.68, 895~903
  4. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
  5. "HCV guidance: recommendations for testing, managing, and treating hepatitis C"[URL]
  6. Yu ML, "2019Taiwan Consensus Statement on the Management of Hepatitis C", J Formos Med Assoc (2020)
  7. Wei L, "Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia : a single-arm, open-label, phase 3 trial", Lancet Gastroenterol Hepatol, 4, pp.127~134 (2019)
  8. Zeuzem S, "Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3infection", N Engl J Med, 378, pp.354~369 (2018)
  9. Brown RS Jr, "Glecaprevir", pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis : the EXPEDITION-8 trial, 2020, pp.72, 441~449
  10. Huang CF, "Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study", BMJ Open, 9, pp.e026703~ (2019)
  11. Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)
  12. Manns M, "Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease : a multicentre, open-label, randomised, phase 2 trial", Lancet Infect Dis, 16, pp.685~697 (2016)
  13. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
  14. Yu ML, "Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions", J Formos Med Assoc, 118, pp.556~564 (2019)
  15. Huang CF, "Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir", asunaprevir, 2020, pp.35, 151~156
  16. Flamm S, "High efficacy and improvement in CPT class with sofosbuvir", velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis, 2019, ~
  17. van der Meer AJ, "Reversion of disease manifestations after HCV eradication", J Hepatol, 65(1 Suppl), pp.S95~S108 (2016)
  18. Chhatwal J, "Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list", Hepatology, 65, pp.777~788 (2017)
  19. Charlton MR, "Ledipasvir", sofosbuvir + ribavirin(LDV, Hepatology, pp.2016, 64[DOI]
  20. Foster GR, "Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis", J Hepatol, 64, pp.1224~1231 (2016)
  21. Barsa JE, "A pleasant dilemma to have : to treat the HCV patient on the waiting list or to treat post-liver transplantation?", Clin Transplant, 29, pp.859~865 (2015)
  22. Bourlière M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)
  23. Gane EJ, "Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen", Hepatology, 66, pp.1083~1089 (2017)
  24. Izumi N, "Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals", Hepatol Int, 12, pp.356~367 (2018)
  25. Poordad F, "Glecaprevir", pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure, 2018, pp.67, 1253~1260
  26. Onofrio FDQ, "Prior therapy with sofosbuvir", velpatasvir associated with reduced response to sofosbuvir, voxilaprevir : results from a Canadian prospective registry, pp.AASLD The Liver Meeting, 2019
  27. Wyles D, "Retreatment of patients who failed glecaprevir", pibrentasvir treatment for hepatitis C virus infection, 2019, pp.70, 1019~1023
  28. de Lédinghen V, "Retreatment with sofosbuvir plus grazoprevir", elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A-or NS3-containing regimen : the ANRS HC34REVENGE study, 2018, pp.66, 1013~1018
  29. Tommaso Lorenzo Parigi, "Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure", Clinical and Molecular Hepatology, 25(4), pp.360~365 (2019), 대한간학회
  30. Chung-Feng Huang, "Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?", Clinical and Molecular Hepatology, 25(2), pp.168~171 (2019), 대한간학회
  31. Ji F, "Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma : a systematic review and meta-analysis", J Hepatol, 71, pp.473~485 (2019)
  32. Ogawa E, "HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma-a practice implication", Clin Infect Dis (2019)
  33. Cabibbo G, "Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients", J Hepatol, 71, pp.265~273 (2019)
  34. Harrod E, "Management of concomitant hepatocellular carcinoma and chronic hepatitis C : a review", Hepatoma Res, 5, pp.28~ (2019)
  35. Dang H, "Cure with interferon free DAA is associated with increased survival in patients with HCV related HCC from both East and West", Hepatoology (2019)
  36. Yeh ML, "Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals", J Gastroenterol Hepatol, 32, pp.1754~1762 (2017)
  37. Liu CJ, "Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV", Gastroenterology, 154, pp.989~997 (2018)
  38. Yeh ML, "Pretreatment hepatitis B viral load predicts long-term hepatitis b response after anti-hepatitis C therapy in hepatitis B", C dual-infected patients, 2019, pp.219, 1224~1233
  39. Mücke MM, "Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 3, pp.172~180 (2018)
  40. Kanda T, "APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation", Hepatol Int, 13, pp.649~661 (2019)
  41. Yeh ML, "Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV", HCV co-infection, 2020, ~
  42. Yu ML, "A sustained virological response to interferon or interferon", ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C : a nationwide, multicentre study in Taiwan, 2006, pp.11, 985~994
  43. Ioannou GN, "HCV eradication induced by directacting antiviral agents reduces the risk of hepatocellular carcinoma", J Hepatol (2017)
  44. Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression", J Hepatol, 67, pp.1204~1212 (2017)
  45. Calvaruso V, "Incidence of hepatocellular carcinoma in patients with HCVassociated cirrhosis treated with direct-acting antiviral agents", Gastroenterology, 155, pp.411~421.e4 (2018)
  46. Yu ML, "Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients : a model for prioritization of treatment", Clin Cancer Res, 23, pp.1690~1697 (2017)
  47. Yu ML, "A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy", Hepatology, 44, pp.1086~1097 (2006)
  48. Huang CF, "Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy", Medicine(Baltimore), 95, pp.e4157~ (2016)
  49. Huang CF, "Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication", J Hepatol, 61, pp.67~74 (2014)
  50. Keol Lee, "Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index", Gut and Liver, 10(5), pp.796~802 (2016), 거트앤리버 소화기연관학회협의회
  51. Ioannou GN, "Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C", J Hepatol, 69, pp.1088~1098 (2018)
  52. Chun HS, "Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C", Eur J Gastroenterol Hepatol, 32, pp.378~385 (2020)
  53. Ioannou GN, "Increased risk for hepatocellular carcinoma persists up to 10years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores", Gastroenterology, 157, pp.1264~1278.e4 (2019)
  54. Perez S, "Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals", PLoS Genet, 15, pp.e1008181~ (2019)
  55. Seong Kyun Na, "Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C", Clinical and Molecular Hepatology, 25(3), pp.234~244 (2019), 대한간학회
  56. El-Serag HB, "The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection", Aliment Pharmacol Ther, 49, pp.1442~1447 (2019)
  57. Butt AA, "Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events", Gastroenterology, 156, pp.987~996.e8 (2019)
  58. Mahale P, "The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection", Gut, 67, pp.553~561 (2018)
  59. Drazilova S, "Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy", Can J Gastroenterol Hepatol, 2018, pp.6150861~ (2018)
  60. Ichikawa T, "Carotid intima-media thickness and small dense low-density lipoprotein cholesterol increase after one year of treatment with directacting antivirals in patients with hepatitis C virus infection", Intern Med, 58, pp.1209~1215 (2019)
  61. Simmons B, "Risk of late relapse or reinfection with hepatitis c virus after achieving a sustained virological response : a systematic review and meta-analysis", Clin Infect Dis, 62, pp.683~694 (2016)
  62. Ingiliz P, "Hepatitis C virus reinfection-more to come?", Lancet Gastroenterol Hepatol, 2, pp.150~151 (2017)
  63. Berenguer J, "Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV", hepatitis C virus coinfected individuals, 2019, pp.33, 685~689
  64. Razavi H., "Mathematical modelling: treatment-as-prevention", The 4th International Symposium on Hepatitis in Substance Users (INHSU 2015) (2015)
  65. World Health Organization, "Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis", WHO Document Production Services, ~ (2016)
  66. Mendizabal M, "Overcoming barriers to hepatitis C elimination", Frontline Gastroenterol, 10, pp.207~209 (2019)
  67. Heffernan A, "Scaling up prevention and treatment towards the elimination of hepatitis C : a global mathematical model", Lancet, 393, pp.1319~1329 (2019)
  68. Yu ML, "A comprehensive people-centered outreach health-care system targeting HCV micro-elimination in hyperendemic areas of taiwan(compact)-establishment of a model toward HCV elimination : interim report", Hepatology, 70(S1), pp.378A~379A (2019)
  69. Huang CF, "Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients", Kidney Int, 97, pp.421~ (2020)
  70. Lawitz E, "Short-duration treatment with elbasvir", grazoprevir and sofosbuvir for hepatitis C : a randomized trial, 2017, pp.65, 439~450
  71. Kumada H, "Efficacy and safety of glecaprevir", pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection, 2018, pp.53, 566~575
  72. Wilson E, "A pilot study of safety and efficacy of HCV retreatment with sofosbuvir", velpatasvir, J Hepatol, pp.2019, 71[DOI]
  73. Lok AS, "Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy", Gastroenterology, 157, pp.1506~1517. e1 (2019)

관련 논문AI추천

Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwo대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisNobuyuki Toshikuni거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제3호Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?Chung-Feng Huang, Ming-Lung Yu대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제2호Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failureAlessio Aghemo, Maria Corina Plaz Torres, Tommaso Lorenzo Parigi대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제4호Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study박은택, 서광일, 윤병철, 이상욱, 한병훈, Weiquan James Li대한간학회 · Clinical and Molecular Hepatology2017 · 제23권 제1호Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma권소영, 김정한, 최원혁, Byung-Chul Yoo, Byung Soo Kwan, Seong Jun Park대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제2호

이 간행물의 다른 논문 (16건)

Management of liver diseases during the pandemic of coronavirus disease-19Young-Sun Lee, Ji Hoon Kim, Jeong Hoon Lee, Ju-Yeon Cho, Korean Association for the Study of the Liver, Soon Sun Kim, 송도선pp. 243-250Novel biomarkers for the management of chronic hepatitis BYasuhito Tanaka, Takako Inouepp. 261-279Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosisHoang Hai, Le Thi Thanh Thuy, Norifumi Kawadapp. 280-293Fecal microbiota transplantation in alcohol related liver diseasesSaggere Muralikrishna Shasthrypp. 294-301Is liver biopsy still useful in the era of non-invasive tests?김자경, Tae Seop Limpp. 302-304
원문 보기